Retatrutide

Mechanism of Action

Retatrutide (LY3437943) — MW 4,731.30 Da · CAS 2381089-83-2 · currently in Phase 3 published research programs (Eli Lilly). A first-in-class synthetic peptide functioning as a simultaneous triple agonist at the GLP-1 receptor (glucagon-like peptide-1), GIP receptor (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). This distinguishes retatrutide mechanistically from single-agonist compounds (e.g., semaglutide, GLP-1R only) and dual-agonist compounds (e.g., tirzepatide, GLP-1R + GIPR). In vitro receptor binding studies have documented agonist activity across all three receptor targets, and preclinical models have been used to investigate downstream signaling in incretin-mediated pathways, hepatic glucose output regulation, and thermogenic signaling cascades. Research applications include multi-receptor pharmacology characterization, comparative incretin agonist studies, and metabolic pathway modeling.

Documented Research Observations

• check_circle Triple agonism observed in receptor binding assays across GLP-1R, GIPR, and GCGR sites.
• check_circle Demonstrated enhanced potency in preclinical metabolic pathway models compared to dual-agonist compounds.
• check_circle Documented effects on hepatic glucose production and lipolytic signaling in in vitro research systems.

Research Applications

Incretin receptor signaling studies, triple-agonist pharmacology research, GLP-1/GIP/glucagon pathway characterization, and multi-target receptor binding assays. Positioned for investigation in metabolic disorder research and comparative mechanistic studies with existing GLP-1 and dual-agonist compounds.